Novel isolation platform with active-release technology for scalable cell therapy manufacturing

Watch the video or view the poster to learn:strategies for enhancing the efficiency, scalability, and consistency of T cell isolation and activation for cell therapy manufacturing; how to isolate both individual and combined CD4+ and CD8+ T cell populations from healthy donor starting material, with high recovery and viability; andhow to ensure the required flexibility and robustness to allow for seamless transitions between the stages of process development and clinical and commercial manufacturing.Ingrid Nyhus Moen is part of the Cell Therapy Process team in Oslo, Norway working on cell therapy process and product development including the CTS™ Detachable Dynabeads™ platform and the CTS™ DynaCellect™ Magnetic Separation System. Ingrid obtained a master’s degree in molecular medicine and a PhD in Medicine and Health Sciences from the Norwegian University of Science and Technology, Trondheim, Norway.